PT  - JOURNAL ARTICLE
AU  - Bernstein, Aaron J.
AU  - Keeman, Renske
AU  - Hurson, Amber
AU  - Blows, Fiona M.
AU  - Bolla, Manjeet K.
AU  - Miller, Jodi L.
AU  - Milne, Roger
AU  - Horlings, Hugo
AU  - van den Broek, Alexandra J.
AU  - Bodelon, Clara
AU  - Hodge, James
AU  - Patel, Alpa
AU  - Teras, Lauren R.
AU  - Canzian, Federico
AU  - Kaaks, Rudolf
AU  - Brenner, Hermann
AU  - Schöttker, Ben
AU  - Behrens, Sabine
AU  - Chang-Claude, Jenny
AU  - Maurer, Tabea
AU  - Obi, Nadia
AU  - Couch, Fergus
AU  - Ali, H. Raza
AU  - Caldas, Carlos
AU  - Andrulis, Irene
AU  - Glendon, Gord
AU  - Mulligan, Anna Marie
AU  - Mesker, Wilma
AU  - Jager, Agnes
AU  - Heemskerk-Gerritsen, Annette
AU  - Devilee, Peter
AU  - Lawrence, Scott M.
AU  - Lissowska, Jolanta
AU  - Mutreja, Karun
AU  - Ahearn, Thomas
AU  - Chanock, Stephen
AU  - Duggan, Maire A.
AU  - Eccles, Diana
AU  - Jones, J. Louise
AU  - Tapper, Will
AU  - Hollestelle, Antoinette
AU  - Hooning, Maartje
AU  - Martens, John
AU  - van Deurzen, Carolien H.M.
AU  - Cox, Angela
AU  - Cross, Simon S.
AU  - Hartman, Mikael
AU  - Li, Jingmei
AU  - Putti, Thomas C.
AU  - Hamann, Ute
AU  - Rashid, Muhammad
AU  - Jakubowska, Ania
AU  - Camp, Nicki
AU  - Cessna, Melissa H.
AU  - Berrington de Gonzalez, Amy
AU  - Bialkowska, Katarzyna
AU  - Gronwald, Jacek
AU  - Lubiński, Jan
AU  - Yadav, Siddhartha
AU  - Lio, Pietro
AU  - Easton, Doug F.
AU  - Abubakar, Mustapha
AU  - Garcia-Closas, Montse
AU  - Pharoah, Paul D.P.
AU  - Schmidt, Marjanka K.
TI  - Spatially-resolved tumour infiltrating immune cells and prognosis in breast cancer
AID  - 10.1101/2024.07.22.24310819
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.22.24310819
4099  - http://medrxiv.org/content/early/2024/07/22/2024.07.22.24310819.short
4100  - http://medrxiv.org/content/early/2024/07/22/2024.07.22.24310819.full
AB  - Background The immune response in breast tumors has an important role in prognosis, but the role of spatial localization of immune cells and of interaction between subtypes is not well-characterized. We evaluated the association between spatially-resolved tissue infiltrating immune cells (TIICs) and breast cancer-specific survival (BCSS) in a large multi-center study.Patients and methods Tissue micro-arrays with tumor cores from 17,265 breast cancer patients of European descent were stained for CD8, FOXP3, CD20, and CD163. We developed a machine learning-based tissue-segmentation and immune cell detection algorithm using Halo™ to score each image for the percentage of marker-positive cells by compartment (overall, stroma, or tumor). We assessed the association between log transformed TIIC scores and BCSS using Cox regression.Results Total CD8+ and CD20+ TIICs (stromal and intra-tumoral) were associated with better BCSS in women with ER-negative (HR per standard deviation = 0.91 [95% CI 0.85 – 0.98] and 0.89 [0.84 – 0.94] respectively) and ER-positive disease (HR = 0.92 [95% CI 0.87 – 0.98] and 0.93 [0.86 – 0.99] respectively) in multi-marker models. In contrast, CD163+ macrophages were associated with better BCSS in ER-negative disease (0.94 [0.87 – 1.00]) and a poorer BCSS in ER-positive disease 1.04 [0.99 – 1.10]. There was no association between FOXP3 and BCSS. The observed associations tended to be stronger for intra-tumoral than stromal compartments for all markers. However, the TIIC markers account for only 7.6 percent of the variation in BCSS explained by the multi-marker fully-adjusted model for ER-negative cases and 3.0 percent for ER-positive cases.Conclusions The presence of intra-tumoral and stromal TIICs is associated with better BCSS in both ER-negative and ER-positive breast cancer. This may have implications for the use of immunotherapy. However, the addition of TIICs to existing prognostic models would only result in a small improvement in model performance.Highlights Stromal and intra-tumoral CD8+ and CD20+ TIICs are associated with better survival in ER+ and ER-breast cancers.Stromal and intra-tumoral CD163+ TIICs are associated with better survival in ER- and poorer survival in ER+ breast cancers.The presence of FOXP3+ tissue infiltrating lymphocytes in breast tumors was not associated with survival in breast cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBCAC was supported by Cancer Research UK grant: PPRPGM-Nov20\100002 and by core funding from the NIHR Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The B-CAST project was supported by the Horizon 2020 Research and Innovation Programs of the European Union B (grant number: 633784) and the NIHR Cambridge Biomedical Research Centre. AJB was supported by the NIH/Oxcam doctoral programme. The funding of the contributing studies is listed in Supplementary Table 8.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent. The ethics committees or institutional review boards responsible for oversight of the individual studies are listed in Supplementary Table 9.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe tissue segmentation and TIIC scores generated by the Halo algorithm together with the phenotype data, the imputed datasets and the analysis code will be available at the European Genome Phenome Archive on publication (https://ega-archive.org/).